checkAd

     117  0 Kommentare MindMed to Present at Upcoming May Medical Conferences

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

    American Psychiatric Association (APA) 2024 Congress, New York, NY
    Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
    Format: Poster
    Presenter: Dan Karlin, MD
    Date: Saturday, May 4, 2024

    Title: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
    Format: Poster
    Presenter: Phong Duong, PharmD
    Date: Saturday, May 4, 2024

    Title: Quantifying the Burden of Undiagnosed Generalized Anxiety Disorder in the US General Adult Population
    Format: Poster
    Presenter: Phong Duong, PharmD
    Date: Saturday, May 4, 2024

    International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
    Title: Health-related Quality of Life Among Adults Diagnosed with Generalized Anxiety Disorder in the United States
    Format: Poster
    Presenter: Phong Duong, PharmD
    Date: Monday, May 6, 2024

    Title: Health Care Resource Use Associated with Undiagnosed and Diagnosed Generalized Anxiety Disorder Among Adults in the United States
    Format: Poster
    Presenter: Phong Duong, PharmD
    Date: Monday, May 6, 2024

    Title: Work Productivity Loss and Activity Impairment among Adults Diagnosed with Generalized Anxiety Disorder in the United States
    Format: Poster
    Presenter: Phong Duong, PharmD
    Date: Wednesday, May 8, 2024

    Lesen Sie auch

    Posters will be available on MindMed’s Company website following the conferences.

    About MindMed

    MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed’s common shares trade on Nasdaq under the symbol MNMD.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors


    MindMed to Present at Upcoming May Medical Conferences Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its …